Renal Disease Treatments: Products and Therapies
- June 2016 •
- 218 pages •
- Report ID: 3944188
Use this report to:
Analyze predominant treatment options for kidney diseases, including pharmaceutical medication, renal replacement therapy, and kidney transplantation.
Analyze the history and current state of renal disease, the background on treatment options, and novel technologies in research and development.
Gain information about the leading and emerging competitors in the current worldwide diagnostic market for kidney diseases.
Analyze renal replacement products and surgical procedures for end stage renal disease
The U.S. market for kidney failure treatment will grow from $39.4 billion in 2016 to nearly $45.6 billion by 2021, with a compound annual growth rate (CAGR) of 3.0% for the period of 2016-2021.
Chronic kidney disease (CKD) treatment dominated the market and will grow from nearly $37.2 billion in 2016 to around $42.8 billion by 2021, rising at a CAGR of 2.8%.
Acute kidney injury (AKI) treatment is expected to increase from nearly $1.8 billion in 2016 to nearly $2.3 billion by 2021 with a CAGR of 5.1%.
STUDY GOALS AND OBJECTIVES
This report provides a comprehensive analysis of the renal disease market and its trends from 2016 through 2021. It details the history and current state of renal disease, background on treatment options, and novel technologies in research and development. In-depth analysis is provided on predominant treatment of kidney diseases, including pharmaceutical medication, renal replacement therapy, and kidney transplantation.
REASONS FOR DOING THE STUDY
The economic burden from chronic kidney disease is alarming. The population of end stage renal disease is just 1% of the U.S. Medicare population but accounts for 7% of the Medicare budget. Kidney failure is the ninth-leading cause of death in the U.S., accounting for about 47,000 fatalities in 2013. Approximately 33 million urrently have chronic kidney disease, while another 20 million are at increased risk for developing chronic kidney disease. More than 600,000 individuals currently are being treated for kidney failure via dialysis or kidney transplant. Nearly 400,000 individuals receive dialysis treatments three or more times each week. Over the last decade, the chronic kidney disease rate has risen more than 25%. During the past five years, the number of new patients with kidney failure has averaged 90,000 to more than 100,000 annually.
In addition to the individuals struggling with chronic kidney disease, more than 600,000 people suffer acute kidney injury in the U.S. each year. The rate of acute kidney injury diagnosis as a percentage of all kidney failure hospitalizations rose from 7.3% in 1980 to 60% in 2005. Experts note that some of the increase may be due to changes in the definition of acute kidney injury. Many of these patients acquire the condition while already hospitalized for other problems. Even worse, the undiagnosed cases of acute kidney injury may be more than the diagnosed cases. While sometimes temporary and reversible, acute kidney injury also may lead to chronic kidney disease.
For both acute and chronic conditions, and outpatient or in-hospital settings, nearly all of these kidney problems require some sort of intervention, whether pharmaceutical, mechanical and/or surgical. This report details the various products and services used to address renal failure. Three categories of treatment are most prevalent: prescription medications, dialysis (hemodialysis, peritoneal dialysis and continuous renal replacement therapy) and surgical intervention, which are often used in combination to treat a single case of renal failure.
The market analysis is intended to provide companies with analytical information to help them make informed decisions about their business strategies. Many times, the ability to successfully execute business strategies hinges on how companies can develop an effective plan with the proper information and data.